These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30037854)

  • 21. Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract.
    Kommoss FK; Tessier-Cloutier B; Witkowski L; Forgo E; Koelsche C; Köbel M; Foulkes WD; Lee CH; Kolin DL; von Deimling A; Howitt BE
    J Pathol; 2022 Jun; 257(2):140-145. PubMed ID: 35218556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.
    Shi Y; Shin DS
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
    Fahiminiya S; Witkowski L; Nadaf J; Carrot-Zhang J; Goudie C; Hasselblatt M; Johann P; Kool M; Lee RS; Gayden T; Roberts CW; Biegel JA; Jabado N; Majewski J; Foulkes WD
    Oncotarget; 2016 Jan; 7(2):1732-40. PubMed ID: 26646792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
    Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
    J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
    Lissanu Deribe Y; Sun Y; Terranova C; Khan F; Martinez-Ledesma J; Gay J; Gao G; Mullinax RA; Khor T; Feng N; Lin YH; Wu CC; Reyes C; Peng Q; Robinson F; Inoue A; Kochat V; Liu CG; Asara JM; Moran C; Muller F; Wang J; Fang B; Papadimitrakopoulou V; Wistuba II; Rai K; Marszalek J; Futreal PA
    Nat Med; 2018 Jul; 24(7):1047-1057. PubMed ID: 29892061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
    Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SWI/SNF chromatin remodeling complex alterations in meningioma.
    Gill CM; Loewenstern J; Rutland JW; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Shrivastava RK
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3431-3440. PubMed ID: 33715086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential therapeutic targets in ARID1A-mutated cancers.
    Bitler BG; Fatkhutdinov N; Zhang R
    Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
    Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary SWI/SNF complex deficiency syndromes.
    Agaimy A; Foulkes WD
    Semin Diagn Pathol; 2018 May; 35(3):193-198. PubMed ID: 29397238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ARID1A loss in cancer: Towards a mechanistic understanding.
    Mathur R
    Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
    Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
    Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
    Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA
    Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
    Oike T; Ogiwara H; Nakano T; Yokota J; Kohno T
    Jpn J Clin Oncol; 2013 Sep; 43(9):849-55. PubMed ID: 23904343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
    Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of the AT-Rich Interaction Domain 1A Gene (
    Li JJ; Lee CS
    Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
    Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.
    Papillon JPN; Nakajima K; Adair CD; Hempel J; Jouk AO; Karki RG; Mathieu S; Möbitz H; Ntaganda R; Smith T; Visser M; Hill SE; Hurtado FK; Chenail G; Bhang HC; Bric A; Xiang K; Bushold G; Gilbert T; Vattay A; Dooley J; Costa EA; Park I; Li A; Farley D; Lounkine E; Yue QK; Xie X; Zhu X; Kulathila R; King D; Hu T; Vulic K; Cantwell J; Luu C; Jagani Z
    J Med Chem; 2018 Nov; 61(22):10155-10172. PubMed ID: 30339381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
    Ramos P; Karnezis AN; Craig DW; Sekulic A; Russell ML; Hendricks WP; Corneveaux JJ; Barrett MT; Shumansky K; Yang Y; Shah SP; Prentice LM; Marra MA; Kiefer J; Zismann VL; McEachron TA; Salhia B; Prat J; D'Angelo E; Clarke BA; Pressey JG; Farley JH; Anthony SP; Roden RB; Cunliffe HE; Huntsman DG; Trent JM
    Nat Genet; 2014 May; 46(5):427-9. PubMed ID: 24658001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.